Skip to Content

Get 14 Days Free Sign Up Sign In

Start Investing
Investing Classroom
Investing Glossary
Tax Planning
Personal Finance
Save for College
Save for Retirement
Invest in Retirement
Mutual Funds
Stocks
ETFs
Bonds
Best Investments
Portfolio
Markets

Investing
Learn
Plan
Research
Portfolio
Markets
For Professionals
Research & Insights
Software & Data Services
Money Management
All Products & Services
Company
Who We Are
Work Here
Newsroom
Investor Relations
Global Contacts

ProQR Therapeutics NV

PRQR Morningstar Rating

Rating as of Dec 6, 2019

Quote
Stock Analysis
News
Price vs Fair Value
Trailing Returns
Financials
Valuation
Operating Performance
Dividends
Ownership
Executive

News

ProQR shares rises on FDA orphan drug designation

Provided by Dow Jones Nov 21, 2019 1:25 PM UTC

Sponsor Center

Site Index

Products

For Individuals
For Advisors
For Retirement Professionals
For Institutions

About Us

Company Site
Careers
Signature Research and Methodology
FAQ
Corrections
Advertising Opportunities
Privacy Policy
User Agreement
Copyright
Reprints Licensing
Regulatory Disclosure

Contact

Support: +1 (312) 424–4288
Feedback
22 W. Washington St.
Chicago, IL 60602

© Copyright 2019 Morningstar, Inc. All rights reserved.
Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.